Welcome Italia selects ADVA FSP 3000 for ultra-high-capacity enterprise services
30.7.2019 09:55:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Welcome Italia has selected its FSP 3000 and ALM fiber monitoring solution to enable assured high-capacity enterprise services throughout Italy. The technology partnership will create scalable fiber optic infrastructure and provide the security and reliability needed for IoT and 5G applications. Stretching over 2,500km and connecting Welcome Italia’s two main data centers, the new network features ADVA’s colorless, directionless and flexgrid multi-degree ROADMs, enabling automatic traffic rerouting for enhanced availability. The solution has also been primed for the comprehensive, low-latency security of ADVA’s ConnectGuard™ Optical encryption technology. ADVA’s partner Sirti is installing the network and will also provide ongoing maintenance and support.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190729005500/en/
Image ADVA's FSP 3000 and ALM fiber monitoring solution will play a key role in delivering assured high-capacity enterprise services throughout Italy (Photo: Business Wire)
”Our aim is to harness the best technology available to provide the ultimate service for our enterprise customers. ADVA’s scalable and efficient solution not only empowers us to deliver fast, flexible and secure business continuity services, but it also helps us reduce cost and lay the foundation for future growth,” commented Nicola Gallico, network manager and founder, Welcome Italia. “This deployment provides concrete answers to the most urgent needs of Italian enterprises. It means they can rely on high-speed, low-latency connectivity backed up by a fully redundant network architecture and protected by real-time fiber monitoring. With the support of the ADVA and Sirti team, we’ll continue to help our customers develop their businesses and seize new opportunities.”
Welcome Italia’s new backbone network serves enterprise clients throughout Italy with points of presence spread across the country. Built on the ADVA FSP 3000, it simplifies network operations and helps to reduce capital and operational expenditure. With its modular architecture, the FSP 3000 gives Welcome Italia the freedom to expand its network as soon as it’s required. The solution is also monitored by the ADVA ALM, which gives real-time insight into the integrity and performance of Welcome Italia’s fiber infrastructure, significantly improving robustness and efficiency. What’s more, the complete network is managed by Ensemble Controller, which combines efficiency in manual operations with programmatic control. This advanced management and domain control solution supports users while also enabling intelligent algorithms to gather data and take autonomous action.
“Welcome Italia chose our technology because it’s the ideal tool for meeting the needs of enterprise customers. It provides superb scalability and cost efficiency, enabling high-speed services that are secure and fully future proof. We’re pleased to be working closely with Welcome Italia’s team to ensure that businesses in this region can capitalize on the most advanced latency-sensitive applications as soon as they hit the market,” commented Marcello Forti, VP, sales, ADVA. “With the flexibility of our ROADM technology and our ALM providing complete fiber network visibility, this solution gives Welcome Italia a new level of agility and reliability. For enterprises across Italy, Welcome Italia’s new network will be the key to harnessing the business opportunities of the IoT.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.advaoptical.com.
About Welcome Italia
Welcome Italia is an Italian telecommunication operator that simplifies your company’s communications with an integrated offer of mobile and fixed line services called Vianova. Vianova combines traditional services, like telephony and ultra-broadband data access, with unified communication and collaboration services like cloud, centrex, mail, meetings, Wi-Fi calls, busy calls, SIM manager. Welcome Italia is also appreciated for the quality of its customer care that answers calls in three rings. Two property data centers host the redundant infrastructure that allows the supply of services for the whole Welcome Italia Group. www.welcomeitalia.it/en
Published by:
ADVA Optical Networking SE, Munich, Germany
www.advaoptical.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190729005500/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@advaoptical.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@advaoptical.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 09:00:00 EET | Press release
Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
Verdict Expected Soon in Klarna’s $8.3 Billion Antitrust Lawsuit Against Google24.2.2026 20:09:00 EET | Press release
Klarna Group plc (NYSE: KLAR) announces that the Patent and Market Court of Sweden (Patent- och marknadsdomstolen) is expected to deliver its verdict on April 15, 2026 in the antitrust damages proceedings brought by Klarna’s subsidiary PriceRunner International AB against Google LLC and Google Ireland Limited. The trial, which ran from October 20 to December 19, 2025, concerned PriceRunner’s claim for approximately $8.3 billion in damages — the largest civil damages claim ever filed in a Swedish court. The Case The claim arises from Google’s abuse of dominance in online comparison shopping, as established by the European Commission in a binding 2017 decision and upheld without reservation by the Court of Justice of the European Union in September 2024. PriceRunner alleges that Google systematically demoted competing price comparison services in its search results while favouring its own Google Shopping product, causing sustained and quantifiable commercial damage to PriceRunner over mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom